Merck Animal Health, a division of Merck & Co. (MRK), announced that it has signed a definitive agreement to acquire the aqua business of Elanco Animal Health (LAN) for $1.3B in cash, consisting of an innovative portfolio of medicines and vaccines, nutritionals and supplements for aquatic species; two related aqua manufacturing facilities in Canada and Vietnam; as well as a research facility in Chile. The acquisition is expected to be completed by mid-year 2024, subject to approvals from regulatory authorities and other customary closing conditions.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on MRK:
- Senate Health, Education, Labor & Pensions Committee holds a hearing
- Merck price target raised to $139 from $122 at Truist
- Merck price target raised to $145 from $135 at Barclays
- Merck & Company Launches 2024 Global Restructuring Program
- Cantor biotech/biopharma analysts to hold analyst/industry conference call